BioCrossroads

What a whirlwind week! Great seeing you at the BioCrossroads Odyssey event Kristin Eilenberg

Leadership transitions at Purdue University are paving the way for advancements in veterinary medicine and animal sciences. The newly appointed dean and former state veterinarian for more than 30 years, Bret Marsh, will focus on addressing gaps and building a strong future for #veterinary #research and practice, furthering Purdue University's continued leadership in strengthening Indiana’s role as a powerhouse in agricultural and life sciences. #veterinarianmedicine #purdue #indiana #lifesciences #agbioscience

Indiana University Foundation has landed a $138 million grant from the Lilly Endowment that will fund construction of a state-of-the-art facility at the 16 Tech Innovation District. The IU Launch Accelerator for Biosciences, known as the IU LAB, will be designed to drive advancements and commercialization in biosciences and develop talent in the sector. Read more about this collaborative effort to fuel workforce development and innovation within life sciences and beyond. #biotech #bioscience #talent #lifesciences

Obesity is a growing global health challenge, and Eli Lilly and Company has made significant strides in advancing obesity treatments with Zepbound. CEO Dave Ricks says the drug is poised to become the company's top-selling drug by 2025, an incredible achievement underscoring the power of innovation happening right here in Indiana. #breakthrough #obesity #diabetes #indiana #lifesciences #drugdiscovery

Infrastructure and innovation go hand in hand in building a resilient and forward-thinking #economy. This recent article highlights the significant strides being made in #bioinnovation and #infrastructure investments in Indiana, as well as the life sciences advancements that will define the future. #lifesciences #indiana #agbioscience #biotech #medtech #innovationeconomy

From the LEAP Innovation district in Lebanon to supporting life sciences industry growth and workforce development, Gov. Eric Holcomb is reflecting on his years in office and the impact those efforts have had on the growth of Indiana's economy during his two terms. He recently sat down with Inside INdiana Business and Gerry Dick - looking ahead to the next few decades and what's on the horizon for the Hoosier state.

Roche has unveiled promising data showing that a simple blood test, being developed in partnership with Eli Lilly and Company, may be able to help determine if someone has #Alzheimer’s disease.   Earlier this year, the U.S. Food and Drug Administration (FDA) granted a #breakthrough device designation to the product, formally called an Elecsys pTa217 assay, a simple blood test that can be used to help identify the presence of #amyloid pathology in patients. This innovation could transform how we approach early #diagnosis and #treatment, making it easier for individuals to receive the right care at the right time. Read more from John Russell with Inside INdiana Business and the Indianapolis Business Journal. #alz #indiana #roche #lilly #breakthrough #fda

Eli Lilly and Company, the company behind the blockbuster obesity treatment Zepbound, is breaking new ground by exploring its potential as a treatment for alcohol and drug dependency. CEO Dave Ricks says Lilly will be the first major drugmaker to study GLP-1 therapies, like Zepbound, specifically for addiction, as emerging research suggests these therapies not only curb food cravings but may also suppress the desire for other substances. #obesity #drugdependency #alcoholaddiction #zepbound #lilly #indiana #lifesciences

On December 4, BioCrossroads' final FrameWORX event of 2024 explored Indiana's leadership position in the exciting, high growth areas of nuclear medicine and radiopharmaceuticals, highlighting Indiana's innovative advancements and strategic initiatives in nuclear medicine. Thank you to all of our amazing expert panelists for sharing their insights, including: Brian Bragg of ZERO Prostate Cancer Geoff Towle of Novartis Kara Weatherman of Purdue University College of Pharmacy Andrew Lake Wooten of Purdue University Kevin Haehl of Nusano Tiffany Olson, retired president of Cardinal Health Nuclear & Precision Health Solutions, and Board Member of Telix Pharmaceuticals Limited and the Education and Research Foundation for Nuclear Medicine and Molecular Imagine, who served as our expert moderator And a special thank you to Indiana University School of Medicine doctors Dr. Mark Green, Dr. Clint Bahler, and Dr. Mark Tann for their in-depth presentation on nuclear medicine diagnostics, therapeutics, and theranostics. Click the link to see a full recap of the presentation and discussions from FrameWORX. #nuclearmedicine #radiopharma #radiopharmaceuticals #indiana #purdue

Researchers at Purdue University and Indiana University School of Medicine are leading the charge in improving the quality of life for individuals with spinal cord injuries. With a $1.5 million grant from the Department of Defense Congressionally Directed Medical Research Programs, the team will test and refine a patent-pending autonomic dysreflexia monitoring device. This groundbreaking technology has the potential to provide real-time monitoring and early alerts for a life-threatening condition that often goes unnoticed, offering a significant step forward in patient safety and healthcare innovation.